Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21F2N3O |
| Molecular Weight | 345.3863 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NC(=O)C1=NN(C2=C1[C@H]3CC[C@@H]2C3)C4=C(F)C=C(F)C=C4
InChI
InChIKey=NTPZXHMTJGOMCJ-WDEREUQCSA-N
InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1
| Molecular Formula | C19H21F2N3O |
| Molecular Weight | 345.3863 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Glenmark Pharmaceuticals has developed tedalinab (also known as GRC-10693) as a potent and selective cannabinoid CB2 receptor agonist for the treatment of osteoarthritis and neuropathic pain. In April 2009, Glenmark announced that tedalinab indicated for the treatment of neuropathic, osteoarthritis and other inflammatory pain disorders had successfully completed Phase I trials in Europe. The drug was ready for phase II of trials; however, information about the further development of this drug is not available.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:24:05 GMT 2025
by
admin
on
Mon Mar 31 20:24:05 GMT 2025
|
| Record UNII |
5R7X34Y6Q1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
67029278
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
PRIMARY | |||
|
DTXSID801030347
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL3234681
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
PRIMARY | |||
|
9257
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
PRIMARY | |||
|
Tedalinab
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
PRIMARY | |||
|
C152534
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
PRIMARY | |||
|
5R7X34Y6Q1
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
PRIMARY | |||
|
300000034436
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
PRIMARY | |||
|
916591-01-0
Created by
admin on Mon Mar 31 20:24:05 GMT 2025 , Edited by admin on Mon Mar 31 20:24:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
very high selectivity of 4700x for CB2 over the related CB1 receptor
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |